FIRST AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • March 2nd, 2009 • Valeant Pharmaceuticals International • Pharmaceutical preparations
This FIRST AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENT (the “First Amendment”) is entered into as of February 10, 2009 (the “First Amendment Effective Date”), by and between Valeant Pharmaceuticals North America, a Delaware corporation having a place of business at One Enterprise, Aliso Viejo, California 92656 (“VALEANT”) and Glaxo Group Limited, a company organized under the laws of England and Wales with its principal place of business at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (“GSK”). VALEANT and GSK are each referred to herein individually as a “Party” or, collectively, as the “Parties.”
